173 related articles for article (PubMed ID: 37106069)
1. METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2.
Zhao S; Song P; Zhou G; Zhang D; Hu Y
Cancer Gene Ther; 2023 Aug; 30(8):1094-1104. PubMed ID: 37106069
[TBL] [Abstract][Full Text] [Related]
2. METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5.
Tang Y; Gao G; Xia WW; Wang JB
Cell Signal; 2022 Nov; 99():110440. PubMed ID: 35985439
[TBL] [Abstract][Full Text] [Related]
3. METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way.
Dou X; Wang Z; Lu W; Miao L; Zhao Y
BMC Pulm Med; 2022 Aug; 22(1):324. PubMed ID: 36008805
[TBL] [Abstract][Full Text] [Related]
4. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
5. Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit-induced long intergenic non-protein coding RNA 1833 N6-methyladenosine methylation promotes the non-small cell lung cancer progression via regulating heterogeneous nuclear ribonucleoprotein A2/B1 expression.
Li D; Fu Z; Dong C; Song Y
Bioengineered; 2022 Apr; 13(4):10493-10503. PubMed ID: 35441574
[TBL] [Abstract][Full Text] [Related]
6. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
7. METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression.
Zhang Y; Liu S; Zhao T; Dang C
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34132367
[TBL] [Abstract][Full Text] [Related]
8. METTL3-mediated the m6A modification of SF3B4 facilitates the development of non-small cell lung cancer by enhancing LSM4 expression.
He G; Gu K; Wei J; Zhang J
Thorac Cancer; 2024 Apr; 15(11):919-928. PubMed ID: 38462740
[TBL] [Abstract][Full Text] [Related]
9. IL-18 serves as a main effector of CAF-derived METTL3 against immunosuppression of NSCLC via driving NF-κB pathway.
Xu L; Li K; Li J; Xu F; Liang S; Kong Y; Chen B
Epigenetics; 2023 Dec; 18(1):2265625. PubMed ID: 37871286
[No Abstract] [Full Text] [Related]
10. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
11. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
Xie H; Yao J; Wang Y; Ni B
Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
[TBL] [Abstract][Full Text] [Related]
12. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
[TBL] [Abstract][Full Text] [Related]
13. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
Li S; Lu X; Zheng D; Chen W; Li Y; Li F
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3485-3499. PubMed ID: 35907010
[TBL] [Abstract][Full Text] [Related]
14. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC.
Cao Y; Di X; Cong S; Tian C; Wang Y; Jin X; Zhao M; Zhou X; Li R; Wang K
Life Sci; 2023 Feb; 315():121359. PubMed ID: 36608868
[TBL] [Abstract][Full Text] [Related]
15. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.
Pan J; Liu F; Xiao X; Xu R; Dai L; Zhu M; Xu H; Xu Y; Zhao A; Zhou W; Dang Y; Ji G
J Exp Clin Cancer Res; 2022 Jan; 41(1):19. PubMed ID: 35012593
[TBL] [Abstract][Full Text] [Related]
16. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
[TBL] [Abstract][Full Text] [Related]
17. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Miao W; Chen J; Jia L; Ma J; Song D
Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
[TBL] [Abstract][Full Text] [Related]
18. METTL3 m6A-dependently promotes miR-21-5p maturation to accelerate choriocarcinoma progression via the HIF1AN-induced inactivation of the HIF1A/VEGF pathway.
Ye K; Li L; Wu B; Wang D
Genes Genomics; 2022 Nov; 44(11):1311-1322. PubMed ID: 36074324
[TBL] [Abstract][Full Text] [Related]
19. Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating Wnt/β-catenin pathway.
Zhao M; Ma W; Ma C
Biomed Pharmacother; 2020 Sep; 129():110461. PubMed ID: 32768951
[TBL] [Abstract][Full Text] [Related]
20. Methylation-mediated loss of SFRP2 enhances invasiveness of non-small cell lung cancer cells.
Zhang X; Rong X; Chen Y; Su L
Hum Exp Toxicol; 2018 Feb; 37(2):155-162. PubMed ID: 29320940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
